AtriCure legal chief sells 9,370 shares at $48.89

AtriCure, Inc. (ATRC) reported that Chief Legal Officer Karl S. Dahlquist sold 9,370 shares of common stock on 2026-08-24 in a sale classified as an open market or private transaction.

Rhea-AI Filing Summary

AtriCure, Inc. (ATRC) reported that Chief Legal Officer Karl S. Dahlquist sold 9,370 shares of common stock on 2026-08-24 in a sale classified as an open market or private transaction. The weighted average sales price was approximately $48.89 per share, with trades executed between $48.88 and $48.89. Following this transaction, Dahlquist directly holds 87,319 AtriCure common shares.

Insider Trade Summary

Net Seller: 9,370 shares

Net Sell 1 txn

Insider Dahlquist Karl S.

Role Chief Legal Officer

Sold 9,370 shs ($458K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	9,370	$48.89	$458K

Holdings After Transaction: Common Stock — 87,319 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $48.88 to $48.89 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 9,370 shares Weighted average sales price: $48.89 per share Share price range: $48.88–$48.89 per share +1 more

4 metrics

Shares sold 9,370 shares Common stock sale on 2026-08-24 by Chief Legal Officer Karl S. Dahlquist

Weighted average sales price $48.89 per share Sale of 9,370 AtriCure common shares on 2026-08-24; trades from $48.88 to $48.89

Share price range $48.88–$48.89 per share Price range of multiple trades comprising the reported insider sale

Shares owned after transaction 87,319 shares Direct holdings of Karl S. Dahlquist following the 2026-08-24 sale

Key Terms

weighted average sales price, open market or private transaction, Form 4

3 terms

weighted average sales price financial

"The price reported above reflects the weighted average sales price."

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AtriCure (ATRC) disclose for Karl S. Dahlquist?

AtriCure disclosed that Chief Legal Officer Karl S. Dahlquist sold 9,370 shares of common stock on 2026-08-24 in an open market or private transaction at a weighted average price of about $48.89 per share.

At what price did Karl S. Dahlquist sell AtriCure (ATRC) shares?

Karl S. Dahlquist’s sale had a reported weighted average sales price of approximately $48.89 per AtriCure share, with individual trade prices ranging from $48.88 to $48.89 per share, according to the Form 4 footnote.

How many AtriCure (ATRC) shares does Karl S. Dahlquist own after the reported sale?

After selling 9,370 shares, Chief Legal Officer Karl S. Dahlquist directly owns 87,319 shares of AtriCure common stock, as reported in the Form 4 filing.

Was the AtriCure (ATRC) insider trade executed as multiple transactions?

Yes. The filing states the sale was executed in multiple trades at prices ranging from $48.88 to $48.89 per share, and the weighted average sales price of about $48.89 is reported.

Does the AtriCure (ATRC) Form 4 mention a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is not marked affirmed; the data indicate the transaction was not reported as being made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 06:50 AM EDT Accepted by SEC EDGAR 08/26/2026 - 06:50 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dahlquist Karl S.

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/24/2026		S		9,370	D	$48.89(1)	87,319	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $48.88 to $48.89 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Karl S. Dahlquist	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)